Table 1.
Clinical characteristics of the patients with NSCLC analyzed in the study
| Parameters | Discovery cohort (N = 194) | Validation cohort (N = 172) | Independent cohort (N = 73) |
|---|---|---|---|
| Age (X ± SD) | 59.2 ± 10.1 | 59.8 ± 10.2 | 57.6 ± 9.1 |
| Gender | |||
| Male | 144 (74.2%) | 136 (79.1%) | 52 (71.2%) |
| Female | 50 (25.8%) | 36 (20.9%) | 21 (28.8%) |
| TNM stage | |||
| I | 87 (44.8%) | 74 (43.0%) | 23 (31.5%) |
| II | 32 (16.5%) | 34 (19.8%) | 20 (27.4%) |
| III | 75 (38.7%) | 64 (37.2%) | 30 (41.1%) |
| Histological type | |||
| ADC | 95 (49.0%) | 89 (51.7%) | 47 (64.4%) |
| SCC | 88 (45.3%) | 76 (44.2%) | 26 (35.6%) |
| ADC/SCC | 11 (5.7%) | 7 (4.1%) | 0 (0.0%) |
| Tumor size (cm) | |||
| < 5 | 108 (55.7%) | 97 (56.4%) | 31 (42.5%) |
| ≥ 5 | 86 (44.3%) | 75 (43.6%) | 42 (57.5%) |
| Differentiation | |||
| Well/moderate | 126 (64.9%) | 105 (61.0%) | 43 (58.9%) |
| Poor | 68 (35.1%) | 67 (39.0%) | 30 (41.1%) |
| Lymphatic metastasis | |||
| No | 105 (54.1%) | 81 (47.1%) | 45 (61.6%) |
| Yes | 89 (45.9%) | 91 (52.9%) | 28 (38.4%) |
| Follow-up time (month) | |||
| Median (IQR) | 37 (24-62) | 36 (23-54%) | 22 (14-35) |
| Smoking history | |||
| No | 79 (40.7%) | 62 (36.0%) | 33 (45.2%) |
| Yes | 115 (59.3%) | 110 (64.0%) | 40 (44.8%) |
| Family cancer history | |||
| No | 161 (83.0%) | 151 (87.8%) | 71 (97.3%) |
| Yes | 33 (17.0%) | 21 (12.2%) | 2 (2.7%) |
SD standard deviation, ADC adenocarcinoma, SCC squamous cell carcinoma, IQR inter-quartile range